Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.

Name: Αlpha¹ Rigor Record — Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
Item: Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
Rating: 59
Author: Αlpha¹

You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, Liu LZ, Zhang WJ, Liu Q, Li HF, Ouyang YF, Duan XT, Wang Q, Peng L, Liang JL, Feng ZK, Qin ZH, Liu X, He ZK, Zhang B, Long GX, Jiang YH, Lei F, Huang PY, Hua YJ, Chen MY

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.5★ (Strong), 0 critical, 3 high issues for “Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.5 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ReportingKey resources partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.

Problems surfaced3 types

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-designed, well-reported phase 3 RCT of camrelizumab plus chemoradiotherapy in high-risk nasopharyngeal carcinoma, with strong reporting of randomisation, ethics, statistics, and transparency (trial registration, CONSORT, limitations, proportional conclusions), and open Dryad data deposition. The main weaknesses are minor reporting gaps: investigational product manufacturers are not stated, analysis code is only in supplemental files rather than a version-controlled repository, and race/ethnicity is not explicitly reported. Copyedit issues are minor typos, including a stray reference appended to the Dryad DOI.

Both independent reviewers agreed on all eight dimension statuses (6 pass, 2 warn) and identical overall scores; the only sub-criterion divergence was how to label the demographics gap (reported but inadequate vs not reported), which does not change the dimension status. Statistics verification recomputed only 4 tests (those with test statistic + df or effect estimate + CI); threshold-only and resampling-based p-values were not machine-verifiable, so the paper's statistics beyond those 4 checks remain unverified rather than confirmed. Citations, claim audit, and integrity checks raised no findings.

6 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 3 via agent-written checks.

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites multiple prior studies, including phase 3 trials of PD-1 inhibitors in NPC and the CONTINUUM study, establishing the rationale. The limitation of 20-30% recurrence despite intensified treatment is acknowledged, and the study addresses this by targeting a high-risk population defined by dynamic response to induction chemotherapy.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The scientific foundation is well established: prior work on risk stratification, PD-1 inhibitors in NPC, and the CONTINUUM/DIPPER trials are cited, and the hypothesis follows logically.

Evidence

direct quote[Introduction, paragraph 4]

“several phase 3 trials have shown that adding programmed death 1 (PD-1) inhibitors to chemotherapy as first line treatment for recurrent or metastatic nasopharyngeal carcinoma provided statistically significantly and clinically meaningful benefits”